Ketamine Tablets for Chronic Migraine: What Patients Should Know

The ketamine migraine dose used in chronic migraine management typically starts low, often 25-50 mg by mouth once or twice daily, then gets adjusted based on response and tolerability. There is no single approved ketamine migraine dose for chronic migraine because ketamine is not FDA-approved for this use. Any prescribing is off-label and individualized by a provider experienced with the medication.

Chronic migraine affects roughly 2% of the global population, according to the World Health Organization, with patients experiencing 15 or more headache days per month. For those who have exhausted conventional treatments, triptans, CGRP inhibitors, beta-blockers, and Botox, ketamine tablets represent an emerging option that some pain specialists are beginning to explore.

What Makes Chronic Migraine So Difficult to Treat

Chronic migraine is not simply a series of bad headaches. It involves central sensitization, a process in which the brain's pain-processing pathways become hyperexcitable over time. This neuroplastic shift means the nervous system essentially learns to amplify pain signals, making each successive episode easier to trigger.

Standard preventive medications work through different mechanisms, blocking CGRP receptors, modulating serotonin, or reducing neuronal excitability, but an estimated 30-40% of patients do not achieve adequate relief from these approaches. These treatment-resistant cases are where ketamine's distinct pharmacology becomes relevant.

How Ketamine May Help Migraines

Ketamine works primarily as an NMDA receptor antagonist. NMDA (N-methyl-D-aspartate) receptors are a subtype of glutamate receptor involved in pain signaling and in the nervous system changes that let pain become self-sustaining. According to the National Institute of Neurological Disorders and Stroke, migraine involves abnormal brain activity that affects nerve signals, chemicals, and blood vessels in the brain.

NMDA receptors play a role in several processes relevant to migraine: central sensitization, the process that makes chronic migraine self-perpetuating; cortical spreading depression, the wave of neuronal activity believed to underlie migraine aura; and wind-up pain, the progressive amplification of pain signals in the trigeminal system.

By blocking NMDA receptors, ketamine may interrupt these processes at a fundamental level. This is a different mechanism than any currently approved migraine medication, which is part of why researchers and clinicians have shown growing interest.

The Glutamate Connection

Migraine research has increasingly focused on glutamate, the brain's primary excitatory neurotransmitter. Researchers have reported elevated glutamate levels in the cerebrospinal fluid of chronic migraine patients. Since ketamine directly modulates glutamate signaling through NMDA receptor blockade, it targets what may be a core driver of migraine chronification.

Evidence for Oral Ketamine in Migraine

Most published research on ketamine for migraine has used intravenous infusions rather than tablets. Oral ketamine tablets are gaining attention as a more practical option for ongoing management, though evidence specific to this route remains limited.

A 2022 retrospective study published in Regional Anesthesia and Pain Medicine examined patients with refractory chronic migraine who received low-dose oral ketamine. The study reported that approximately 50% of patients experienced a meaningful reduction in headache frequency and severity over a 3-month period. Smaller case series have described reductions in monthly migraine days from an average of 20 or more to fewer than 12 in responders, decreased reliance on acute rescue medications, and improved functional capacity and quality of life scores.

No large randomized controlled trials specific to oral ketamine tablets for migraine have been completed. The current evidence is preliminary and comes mainly from retrospective studies and case series, which cannot establish cause and effect the way a controlled trial can.

Typical Dosing Approaches

There is no standardized protocol for oral ketamine tablets in migraine. Clinicians experienced with this approach generally start low and adjust based on response.

Starting Doses

Most providers begin conservatively, often at 25-50 mg taken once or twice daily. This allows assessment of tolerability before any upward adjustment.

Maintenance Dosing

Patients who respond may be maintained on doses ranging from 50-200 mg daily, often divided into two or three doses. The goal is the minimum effective dose that provides meaningful migraine reduction without problematic side effects. Oral ketamine tablets for migraine are typically compounded rather than commercially manufactured. Our guide to compounded ketamine tablets explains how that process can affect dose consistency. For broader context on how providers approach dose titration, see our guide on optimizing ketamine dosing.

Rescue Use vs. Preventive Use

Some providers prescribe oral ketamine tablets as a rescue medication for severe migraine attacks that do not respond to first-line treatments. Others use a daily preventive approach. A smaller number combine both strategies, using a lower daily preventive dose with the option for a slightly higher dose during acute attacks.

How Tablets Compare to IV for Migraine

IV ketamine infusions for migraine typically involve multi-day hospital or clinic-based protocols. Oral tablets work differently in the body. See our comparison of oral versus IV ketamine and our review of bioavailability studies for more on how the two routes differ pharmacologically. The tradeoffs below summarize what that difference means for migraine patients.

Side Effects and Safety Considerations

The side effects of oral ketamine tablets are dose-dependent and generally manageable at the doses used for migraine. Common effects include dizziness and lightheadedness, which is the most common and typically mild; nausea, which can often be addressed with timing adjustments or anti-nausea medication; dissociation, usually mild at low doses, with patients often describing feeling slightly detached; and fatigue or drowsiness, especially in the first 1-2 hours after dosing.

Patients should not drive or operate heavy machinery after taking ketamine tablets, particularly in the hours immediately following a dose.

Long-Term Safety

Chronic use of ketamine raises questions about urological and hepatic health. At the low doses typically used for migraine, well below recreational levels, these risks appear minimal but still require monitoring. Regular check-ups, including liver function tests and urinary symptom assessment, are standard practice for patients on ongoing ketamine therapy. Our article on long-term outcomes covers this in more depth.

What Patients Report

Patients who respond to oral ketamine for migraine often describe a gradual reduction in both the frequency and intensity of attacks over the first 4-8 weeks. Some report that their migraines become more responsive to standard acute treatments, such as triptans and NSAIDs, even when ketamine does not eliminate attacks entirely.

Not everyone responds. Estimates suggest that roughly half of treatment-resistant migraine patients may see meaningful benefit from ketamine, while the other half do not experience significant improvement. These figures come from small retrospective studies and case series rather than large trials, so individual results can vary.